305 related articles for article (PubMed ID: 34509050)
1. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma.
Xie Y; Olkhov-Mitsel E; Alminawi S; Slodkowska E; Downes MR
Pathol Res Pract; 2021 Oct; 226():153607. PubMed ID: 34509050
[TBL] [Abstract][Full Text] [Related]
2. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
5. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
[TBL] [Abstract][Full Text] [Related]
7. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
8. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
10. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
11. Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system.
Laurinaviciene A; Plancoulaine B; Baltrusaityte I; Meskauskas R; Besusparis J; Lesciute-Krilaviciene D; Raudeliunas D; Iqbal Y; Herlin P; Laurinavicius A
Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S10. PubMed ID: 25565007
[TBL] [Abstract][Full Text] [Related]
12. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis.
Loughrey MB; Bankhead P; Coleman HG; Hagan RS; Craig S; McCorry AMB; Gray RT; McQuaid S; Dunne PD; Hamilton PW; James JA; Salto-Tellez M
Histopathology; 2018 Aug; 73(2):327-338. PubMed ID: 29575153
[TBL] [Abstract][Full Text] [Related]
13. A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
Tsuji K; Kaneko M; Harada Y; Fujihara A; Ueno K; Nakanishi M; Konishi E; Takamatsu T; Horiguchi G; Teramukai S; Ito-Ihara T; Ukimura O
Eur Urol Oncol; 2024 Apr; 7(2):258-265. PubMed ID: 38065702
[TBL] [Abstract][Full Text] [Related]
14. iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona.
Brunelli M; Beccari S; Colombari R; Gobbo S; Giobelli L; Pellegrini A; Chilosi M; Lunardi M; Martignoni G; Scarpa A; Eccher A
Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S12. PubMed ID: 25565219
[TBL] [Abstract][Full Text] [Related]
15. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
16. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
[TBL] [Abstract][Full Text] [Related]
17. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
18. Virtual multiplex immunohistochemistry: Application on cell block of effusion and aspiration cytology.
Chan RCK; Li JJX; Yeung W; Chan AWH
Diagn Cytopathol; 2020 May; 48(5):417-423. PubMed ID: 32017459
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
